Press Releases

Media Contact: press@diabetes.org

The most recent press releases from the American Diabetes Association:

July 31, 2019
Updates to the 2019 Standards of Medical Care in Diabetes Issued Today by the American Diabetes Association®
The American Diabetes Association® (ADA) issued important updates to the 2019 Standards of Medical Care in Diabetes (Standards of Care) today, in annotations as the Living Standards of Care, with the changes focusing on new metrics for continuous glucose monitoring (CGM) utilization and new medication options and recommendations for youth and adults with type 2 diabetes.

July 22, 2019
The American Diabetes Association® Applauds the Insulin Price Reduction Act, Introduced Today by the Senate Diabetes Caucus
The American Diabetes Association (ADA) strongly supports the introduction of the Insulin Price Reduction Act in the United States Senate.

July 18, 2019
Patient Groups Express Strong Opposition to Medicaid Block Grants
Today, 27 patient groups submitted a letter to Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma expressing strong opposition to policies that would allow states to apply for block grants or per capita caps for their Medicaid programs.

July 12, 2019
National Diabetes Coalition Urges Louisiana Residents with Diabetes to Prepare for Tropical Storm Barry
The Diabetes Disaster Response Coalition (DDRC), which is comprised of the nation’s leading diabetes organizations, is urging all people with diabetes and their loved ones to prepare by putting together a diabetes kit and making a plan to stay healthy and safe during the storm and in its aftermath.

July 5, 2019
Court Urged to Prioritize Patients and Uphold Health Care Law
Protections for Pre-Existing Conditions and Coverage Standards at Risk.

June 17, 2019
American Diabetes Association® Celebrates 70 Years of Fun, Educational Camps for Children
For 70 years, the American Diabetes Association (ADA) has hosted summer camps for children and teens with type 1 diabetes. In 2019 nearly 7,000 campers, their siblings, and children at-risk of type 2 diabetes, ages 4-17, will attend one of 80 camp sessions nationwide and enjoy a traditional summer camp experience in a medically-safe environment.

June 11, 2019
Oral Semaglutide Reduces Occurrence of Major Cardiac Events in People with Type 2 Diabetes With High Cardiovascular Risk
PIONEER 6 study of 3,183 adults presented today at the ADA’s Scientific Sessions.

June 11, 2019
Safety of Linagliptin for Adults with Type 2 Diabetes Who Have High Risk of Cardiovascular and/or Renal Disease Examined in CARMELINA
International trial of nearly 7,000 people indicates a noninferior risk, presented at the ADA’s Scientific Sessions.

June 11, 2019
Canagliflozin Shown to Improve Cardiovascular and Renal Outcomes in People with Type 2 Diabetes and Kidney Disease
CREDENCE trial finds improved overall cardiovascular and kidney outcomes, according to results presented today at ADA’s Scientific Sessions.

June 10, 2019
Dapagliflozin Reduces Progression of Kidney Disease and Renal Death in People with Type 2 Diabetes
Sub-analysis of data from DECLARE-TIMI 58 trial shows a 47% reduction of composite kidney function decline, end-stage renal disease or death, presented today at the ADA’s Scientific Sessions.

June 10, 2019
Dulaglutide is Safe and Effective for People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease
Analysis of AWARD-7 study determined dulaglutide reduced events associated with end-stage kidney disease.

June 10, 2019
Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk
Results of CAROLINA trial, a multi-center, international clinical trial of more than 6,000 adults and the longest-running study dedicated to cardiovascular outcomes in people with type 2 diabetes, presented at ADA’s Scientific Sessions.

June 10, 2019
Access to Continuous Glucose Monitors in Pediatric Diabetes Populations Improves Glycemic Control, Reduces Hypoglycemia and Improves Satisfaction with Diabetes Care and Technology Use
Studies examining effectiveness of CGM among children, teens and young adults with type 1 diabetes presented at the ADA’s Scientific Sessions.

June 9, 2019
Dulaglutide Reduces Cardiovascular Disease in People with Type 2 Diabetes
Presented at ADA’s Scientific Sessions, REWIND trial confirms dulaglutide reduces CVD risk regardless of CV history.

June 9, 2019
Type 1 Diabetes May Affect Brain Development, Beginning in Early Childhood
DirecNet study indicates youth with early-onset T1D have mild but detectable differences in brain development, based on research presented at the ADA’s Scientific Sessions.

June 9, 2019
Two RISE Clinical Trials in Youth and Adults with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes Reveal Surprising Differences in Beta-Cell (β-cell) Function During and After Treatment
RISE researchers present Adult Medication Study results at the ADA’s Scientific Sessions and share the first direct comparison for youth and adult studies.

June 9, 2019
Teplizumab Delays Clinical Diagnosis of Type 1 Diabetes, an Average of Two Years, According to Study Presented at ADA’s Scientific Sessions
TrialNet research indicates immune therapy can slow the progression to disease in people identified as high risk for developing T1D.

June 9, 2019
Consistent Use of Diabetes Technology Across Multiple Environments Benefits Youth with Diabetes
Use of diabetes devices at school and camp shows improved outcomes and more time-in-range for youth with type 1 diabetes, presented at the ADA’s Scientific Sessions.

June 9, 2019
Delayed Onset of Type 2 Diabetes by Six Years or More Significantly Reduces Risk of Cardiovascular Disease and Microvascular Disease
Analysis of 30-year follow up of more than 500 adults in China examines the extent of increased cardiovascular risk can be attributed to diabetes.

June 8, 2019
Insulin-Producing Beta Cells Are Not Irreversibly Lost in Early Type 2 Diabetes
Analysis of data over a two-year period finds losing weight and minimizing weight regain can potentially lead to remission of type 2 diabetes.

  • Last Reviewed: November 18, 2013
  • Last Edited: July 30, 2019